BC 3425

N/A

Report date: 2023/02/15 18:04:25

Base Information

Drug NameBC 3425
Drug Alias NameBC-3425
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsTumor necrosis factor receptor superfamily member 9 agonistsT lymphocytes stimulants
TargetsTumor necrosis factor receptor superfamily member 9
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesWuxi BioCity
China Registration ClassN/A

Develop Information

Active CompaniesWuxi BioCity
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A